All In Biotech

Drug Trial Radar · NCT02960763

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 742 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

742

Actual

Start

Feb 24, 2017

Primary completion

Sep 28, 2020

Study completion Sep 1, 2021

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; National Institute of Mental Health (NIMH)
First posted
Nov 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).

Conditions

  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Treatment-Refractory Depression
  • Late Life Depression
  • Geriatric Depression

Interventions

  • Aripiprazole AugmentationDrug

    Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.

  • Bupropion AugmentationDrug

    Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.

  • Switch to bupropionDrug

    Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.

  • Lithium AugmentationDrug

    Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.

  • Switch to nortriptylineDrug

    Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Psychological Well-BeingTime frame: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
  2. Number of Participants With Remission From DepressionTime frame: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
  3. Serious Adverse EventsTime frame: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA Late-Life Mood, Stress, and Wellness Research Program

    Los Angeles, California

  • Washington University School of Medicine Healthy Mind Lab

    St Louis, Missouri

  • Columbia University Adult and Late Life Depression Clinic

    New York, New York

  • UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program

    Pittsburgh, Pennsylvania

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.